Registered entities
Innovation
6 patent families — focus: Chemistry & metallurgy, Human necessities; filing pace slowing. Cited 269 times.
| Year | Filings |
|---|---|
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 4 |
| 2023 | 6 |
| 2024 | 1 |
| 2025 | 2 |
Social engagement
Social engagement: 55.5K social following, 5 posts in the last 12 months — below the industry typical range.
Investor mix
32 investors on record; lead investors include Baillie Gifford, F-Prime Capital, ORI Capital, Deerfield; 2 have since exited.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 15 | 47% |
| Angel & family office | 1 | 3% |
| Bank & private debt | 3 | 9% |
| Other / undisclosed | 13 | 41% |
Hiring activity
Hires occasionally
2 roles tracked across 2 of the last 12 months
1 May 2026 · Senior Medical Science Liaison - Gene Therapy US Medical Affairs · Boston
24 Feb 2026 · Medical Science Liaison - Gene Therapy US Medical Affairs
13 Sep 2025 · Executive Director, Regulatory Science · Boston
26 Jan 2025 · Therapeutic Operations Lead - Benelux · Leiden
Based on job postings tracked across public sources.
